Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 14, 2012
[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)]Michiyo Saimura, Keisei Anan, Shoshu Mitsuyama, et al.
Breast Cancer Research and Treatment|November 20, 2012
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)Makoto Kubo, Noriko Kanaya, Karineh Petrossian, et al.
Breast Cancer (Tokyo, Japan)|September 29, 2022
A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapyShozo Ohsumi, Reiki Nishimura, Norikazu Masuda, et al.
Clinical Breast Cancer|March 12, 2024
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero SubtypesReiki Nishimura, Yoshitaka Fujiki, Tetsuhiko Taira, et al.
Annals of Surgical Oncology|January 8, 2013
Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrenceMakoto Ishitobi, Yasuhiro Okumura, Nobuyuki Arima, et al.
Breast Cancer Research and Treatment|May 23, 2019
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort studyShinji Ohno, Hirofumi Mukai, Kazutaka Narui, et al.
The Lancet. Oncology|December 1, 2015
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trialTsutomu Takashima, Hirofumi Mukai, Fumikata Hara, et al.
Japanese Journal of Clinical Oncology|June 3, 2005
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanesMasakazu Toi, Toshiaki Saeki, Kenjiro Aogi, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2025
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancerReiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 14, 2012
[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)]Michiyo Saimura, Keisei Anan, Shoshu Mitsuyama, et al.
Breast Cancer Research and Treatment|November 20, 2012
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)Makoto Kubo, Noriko Kanaya, Karineh Petrossian, et al.
Breast Cancer (Tokyo, Japan)|September 29, 2022
A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapyShozo Ohsumi, Reiki Nishimura, Norikazu Masuda, et al.
Clinical Breast Cancer|March 12, 2024
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero SubtypesReiki Nishimura, Yoshitaka Fujiki, Tetsuhiko Taira, et al.
Annals of Surgical Oncology|January 8, 2013
Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrenceMakoto Ishitobi, Yasuhiro Okumura, Nobuyuki Arima, et al.
Breast Cancer Research and Treatment|May 23, 2019
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort studyShinji Ohno, Hirofumi Mukai, Kazutaka Narui, et al.
The Lancet. Oncology|December 1, 2015
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trialTsutomu Takashima, Hirofumi Mukai, Fumikata Hara, et al.
Japanese Journal of Clinical Oncology|June 3, 2005
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanesMasakazu Toi, Toshiaki Saeki, Kenjiro Aogi, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2025
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancerReiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
Pageof 8